Overview

Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer

Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
Pembrolizumab alone and in combination with acalabrutinib in subjects with advanced non-small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Acerta Pharma BV
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Acalabrutinib
Pembrolizumab